Alpha-glucosidase inhibitors for type 2 diabetes mellitus

Cochrane Database of Systematic Reviews

Volumn 2009, Issue 1, 2005, Pages

  Van de Laar, Floris A ^a   Lucassen, Peter LBJ ^a   Akkermans, Reinier P ^a   Van de Lisdonk, Eloy H ^a   Rutten, Guy EHM ^b   Van Weel, Chris ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE; ANTIDIABETIC AGENT; DRUG DERIVATIVE; ENZYME INHIBITOR; GLUCOSAMINE; IMINOSUGAR; INOSITOL; MIGLITOL; VOGLIBOSE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; HUMAN; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ACARBOSE; ALPHA-GLUCOSIDASES; DIABETES MELLITUS, TYPE 2; ENZYME INHIBITORS; GLUCOSAMINE; HUMANS; HYPOGLYCEMIC AGENTS; IMINO PYRANOSES; INOSITOL; RANDOMIZED CONTROLLED TRIALS;

EID: 21844442157     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003639.pub2     Document Type: Article

References (120)

1. Braun D, Schonherr U, Mitzkat H-J. Efficacy of acarbose monotherapy in patients with type 2 diabetes: A double-blind study conducted in general practice. Endocrinology & Metabolism 1996;3(4):275-280. [MEDLINE: 355]
2. Buchanan DR, Collier A, Rodrigues E, Millar AM, Gray RS, Clarke BF. Effectiveness of acarbose, an alpha-glucosidase inhibitor, in uncontrolled non-obese non-insulin dependent diabetes. European Journal of Clinical Pharmacology 1988;34(1):51-53. [MEDLINE: 121]
3. Calle-Pascual A, Garcia-Honduvilla J, Martin-Alvarez PJ, Calle JR, Maranes JP. Influence of 16-week monotherapy with acarbose on cardiovascular risk factors in obese subjects with non-insulin-dependent diabetes mellitus: a controlled, double-blind comparison study with placebo [letter]. Diabetes & Metabolism 1996;22(3):201-202. [MEDLINE: 94]
4. Campbell I, Robertson-Mackay F, Streets E, Gibbons F, Holman RR. Maintenance of glycaemic control with acarbose in diet treated Type 2 diabetic patients. Diabetic Medicine 1998;15(Suppl 2):S29-30. [MEDLINE: 506]
5. Holman RR, Robertson-Mackay F, Gibbons F, Montegriffo E, Campbell I. Acarbose maintains glycaemic control in diet treated type 2 diabetes. Clinical Science 1999;96:7p. [MEDLINE: 505]
6. Chan JC, Chan KW, Ho LL, Fuh MM, Horn LC, Sheaves R, et al. An Asian multicenter clinical trial to assess the efficacy and tolerability of acarbose compared with placebo in type 2 diabetic patients previously treated with diet. Asian Acarbose Study Group. Diabetes Care 1998;21(7):1058-1061. [MEDLINE: 11]
7. Chiasson JL, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial [see comments]. Annals of Internal Medicine 1994;121(12):928-935. [MEDLINE: 19]
8. Josse RG. Acarbose for the treatment of type II diabetes: the results of a Canadian multi-centre trial [published erratum appears in Diabetes Res Clin Pract 1995 Sep;29(3):215]. Diabetes Research and Clinical Practice 1995;28 Suppl:S167-S172. [MEDLINE: 15]
9. Rodger NW, Chiasson JL, Josse RG, Hunt JA, Palmason C, Ross SA, et al. Clinical experience with acarbose: results of a Canadian multicentre study. Clinical and investigative medicine. Medecine clinique et experimentale 1995;18(4):318-324. [MEDLINE: 148]
10. Ross S, Hunt J, Josse R, Mukherjee J, Palmason C, Rodger W, et al. Acarbose significantly improves glucose control in non-insulin-dependent diabetes mellitus subjects (NIDDM): results of the mult-centre Canadian trial. Diabetes 1992;41(Suppl. 1):193A. [MEDLINE: 512]
11. Wolever TM, Chiasson JL, Josse RG, Hunt JA, Palmason C, Rodger NW, et al. No relationship between carbohydrate intake and effect of acarbose on HbA1c or gastrointestinal symptoms in type 2 diabetic subjects consuming 30-60% of energy from carbohydrate. Diabetes Care 1998;21(10):1612-1618. [MEDLINE: 151]
12. Wolever TM, Chiasson JL, Josse RG, Hunt JA, Palmason C, Rodger NW, et al. Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes. International Journal of Obesity and Related Metabolic Disorders 1997;21(9):756-763. [MEDLINE: 152]
13. Chiasson JL, Naditch L. The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes. Diabetes Care 2001;24(6):989-94. [MEDLINE: 469]
14. Wolever TMS, Assiff L, Basu T, Chiasson J-L, Boctor M, Gerstein HC, et al. Miglitol, an alpha-glucosidase inhibitor, prevents the metformin-induced fall in serum folate and vitamin B12 in subjects with type 2 diabetes. Nutrition Research 2000;20(10):1447-1456. [MEDLINE: 93]
15. Coniff RF, Shapiro JA, Seaton TB. Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus. Archives of Internal Medicine 1994;154(21):2442-2448. [MEDLINE: 123]
16. Innerfield RJ, Coniff RF. A multi-center, double-blind, placebo-controlled study of the long-term efficacy and safety of acarbose (Bay g 5421) in the Rx of obese patients with NIDDM Rxed by diet alone. Diabetes 1990;39(Suppl. 1):211A. [MEDLINE: 511]
17. Coniff RF, Shapiro JA, Seaton TB, Bray GA. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. The American Journal of Medicine 1995;98(5):443-51. [MEDLINE: 18]
18. Coniff RF, Shapiro JA, Robbins D, Kleinfield R, Seaton TB, Beisswenger P, et al. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study. Diabetes Care 1995;18(6):817-824. [MEDLINE: 17]
19. Dedov II, Balabolkin MI, Mkrtumyan AM, Ametov AS, Kakhnovsky IM, Chazova TE, et al. Glucobai therapy of diabetes mellitus. [Russian]. Problemy Endokrinologii 1995;41(3):11-13. [MEDLINE: 424]
20. Delgado H, Lehmann T, Bobbioni-Harsch E, Ybarra J, Golay A. Acarbose improves indirectly both insulin resistance and secretion in obese type 2 diabetic patients. Diabetes & Metabolism 2002;28(3):195-200. [MEDLINE: 484]
21. Drent ML, The Dutch Miglitol Investigators Group. Miglitol as single oral hypoglycemic agent in type 2 diabetes. Diabetologia 1994;37(Suppl. 1):A211. [MEDLINE: 494]
22. Drent ML, Tollefsen AT, van Heusden FH, Hoenderdos EB, Jonker JJ, van der Veen EA. Dose-dependent efficacy of miglitol, an alpha-glucosidase inhibitor, in type 2 diabetic patients on diet alone: results of a 24-week double-blind placebo-controlled study. Diabetes, Nutrition & Metabolism 2002;15(3):152-159. [MEDLINE: 489]
23. Fischer S, Hanefeld M, Spengler M, Boehme K, Temelkova-Kurktschiev T. European study on dose-response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus: efficacy and safety of low and high doses. Acta Diabetologica 1998;35(1):34-40. [MEDLINE: 128]
24. Gentile S, Turco S, Guarino G, Oliviero B, Rustici A, Torella R. Non-insulin-dependent diabetes mellitus associated with nonalcoholic liver cirrhosis: an evaluation of treatment with the intestinal alpha-glucosidase inhibitor acarbose [Diabete mellito non insulino-dipendente associato a cirrosi epatica non etilica: valutazione del trattamento con un inhibitore delle alpha-glucosidasi intestinali, acarbose]. Annali Italiani di Medicina Interna 1999;14(1):7-14. [MEDLINE: 130]
25. Gentile S, Turco S, Persico M, Pananello A, Conte S, Gesuè L, et al. Efficacy of acarbose in the control of diabetes mellitus associated with liver cirrhosis. Journal of Hepatology 1997;26(Suppl 1):S101. [MEDLINE: 500]
26. Gentile S, Turco S, Persico M, Panariello A, Conte S, De Seta M, Gesuè L, et al. The acarbose tretament of type 2 diabetes mellitus associated with liver cirrhosis. Diabetologia 1997;40:A306. [MEDLINE: 497]
27. Fischer S, Patzak A, Rietzsch H, Schwanebeck U, Kohler C, Wildbrett J, et al. Influence of treatment with acarbose or glibenclamide on insulin sensitivity in type 2 diabetic patients. Diabetes, Obesity and Metabolism 2003;5(1):38-44. [MEDLINE: 485]
28. Haffner SM, Hanefeld M, Fischer S, Fucker K, Leonhardt W. Glibenclamide, but not acarbose, increases leptin concentrations parallel to changes in insulin in subjects with NIDDM. Diabetes Care 1997;20(9):1430-1434. [MEDLINE: 137]
29. Hanefeld M, Haffner SM, Menschikowski M, Koehler C, Temelkova-Kurktschiev T, Wildbrett J, Fischer S. Different effects of acarbose and glibenclamide on proinsulin and insulin profiles in people with Type 2 diabetes. Diabetes Research and Clinical Practice 2002;55(3):221-227. [MEDLINE: 481]
30. Hanefeld M, Fischer S, Schulze J, Spengler M, Wargenau M, Schollberg K, et al. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. Diabetes Care 1991;14(8):732-737. [MEDLINE: 81]
31. Leonhardt W, Hanefeld M, Fischer S, Schulze J, Spengler M. Beneficial effects on serum lipids in noninsulin dependent diabetics by acarbose treatment. Arzneimittelforschung 1991;41(7):735-738. [MEDLINE: 109]
32. Hillebrand I, Englert R. Efficacy and tolerability of a 12-week treatment with acarbose (BAY g5421), miglitol (BAY m1099) and glibenclamid. Diabetes 1987;26:134A. [MEDLINE: 515]
33. Fölsch UR, Spengler M, Boehme K, Sommerauer B. Efficacy of glucosidase inhibitors compared to sulphonylureas in the treatment and metabolic control of diet treated Type II diabetic subjects: Two long-term comparative studies. Diabetes, Nutrition & Metabolism 1990;3(Suppl. 1):63-68. [MEDLINE: 82]
34. Hoffmann J. Acarbose and Glibenclamid in Type-II Diabetes. A Comparative Study on Efficacy and Side Effects [Acarbose und Glibenclamid bei Typ-II-Diabetes. Eine Vergleichsstudie zu Wirksamkeit und Nebenwirkungen]. Münchener Medizinische Wochenschrift 1990;132(31-32):487-490. [MEDLINE: 10]
35. Hoffmann, J. Adjustment of metabolism and eating behaviour of type II diabetics. Results of a six-months treatment with glibenclamide, respectively with acarbose [Stoffwechseleinstellung und Essverhalten von Typ-II-Diabetikern. Ergebnisse einer sechsmonatigen Behandlung mit Glibenclamid bzw. mit Acarbose]. Zeitschrift für Allgemeinmedizin 1992;68(29):970-977. [MEDLINE: 8]
36. Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study. Diabetes Care 1994;17(6):561-566. [MEDLINE: 20]
37. Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study. American Journal of Medicine 1997;103(6):483-490. [MEDLINE: 13]
38. Holman RR, Cull CA, Turner RC. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44) [see comments] [published erratum appears in Diabetes Care 1999 Nov;22(11):1922]. Diabetes Care 1999;22(6):960-4. [MEDLINE: 4]
39. Holmes D, Raccah D, Escobar-Jimenez F, Standl E. Targeting postprandial hyperglycemia in patients with type 2 diabetes: nateglinide vs acarbose. Diabetologia 2001;44(Suppl 1):A215. [MEDLINE: 487]
40. Holmes D, Raccah D, Escobar-Jimenez F, Standl E. Targeting postprandial hyperglycemia to achieve glycemic control in patients with type 2 diabetes: a comparison of nateglinide and acarbose [Poster presentation]. EASD Congress 9-13 september 2001, Glasgow (UK). [MEDLINE: 486]
41. Raccah D, Escobar-Jimenez F, Gomis R, Holmes D, Standl E. Targeting prandial glucose with nateglinide and acarbose in the treatment of type 2 diabetes: a double-blind clinical comparison. Unpublished Document. [MEDLINE: 493]
42. Hotta N, Kakuta H, Sano T, Matsumae H, Yamada H, Kitazawa S, et al. Long-term effect of acarbose on glycaemic control in non-insulin-dependent diabetes mellitus: a placebo-controlled double-blind study. Diabetic Medicine 1993;10(2):134-138. [MEDLINE: 21]
43. Sakamoto N, Hotta N, Kakuta H, Sano T, Yamada H, Matsumae H, et al. An investigation into the efficacy of long term usage of Bay g 5421 (acarbose) for non-insulin dependent diabetes. A placebo controlled, double blind trial [japanese]. Rinshou to Kenkyu 1990;67(1):219-233. [MEDLINE: 504]
44. Johnston PS, Lebovitz HE, Coniff RF, Simonson DC, Raskin P, Munera CL. Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients. The Journal of Clinical Endocrinology and Metabolism 1998;83(5):1515-1522. [MEDLINE: 141]
45. Johnston PS, Feig PU, Coniff RF, Krol A, Davidson JA, Haffner SM. Long-term titrated-dose alpha-glucosidase inhibition in non-insulin-requiring Hispanic NIDDM patients. Diabetes Care 1998;21(3):409-415. [MEDLINE: 143]
46. Johnston PS, Feig PU, Coniff RF, Krol A, Kelley DE, Mooradian AD. Chronic treatment of African-American type 2 diabetic patients with alpha-glucosidase inhibition. Diabetes Care 1998;21(3):416-422. [MEDLINE: 142]
47. Kawamori R, Toyota T, Oka Y, Yamada A, Iwamoto Y, Tajima N, et al. Improvement of glycaemic control following 12-week treatment with miglitol in Japanese type 2 diabetics: a double-blind, randomized, placebo- and voglibose-controlled trial. Poster display, IDF Congress Paris august 25 2003. [MEDLINE: 510]
48. Kovacevic I, Profozic V, Skrabalo Z, Cabrijan T, Zjacic-Rotkvic V, Goldoni V, et al. Multicentric clinical trial to assess efficacy and tolerability of acarbose (BAY G 5421) in comparison to glibenclamide and placebo. Diabetologia Croatica 1997;26(2):83-89. [MEDLINE: 316]
49. Josse RG, Chiasson JL, Ryan EA, Lau DC, Ross SA, Yale JF, et al. Acarbose in the treatment of elderly patients with type 2 diabetes. Diabetes Research and Clinical Practice 2003;59(1):37-42. [MEDLINE: 483]
50. Meneilly GS, Ryan EA, Radziuk J, Lau DC, Yale JF, Morais J, et al. Effect of acarbose on insulin sensitivity in elderly patients with diabetes. Diabetes Care 2000;23(8):1162-1167. [MEDLINE: 101]
51. Marena S, Pagani A, Montegrosso G, Boella G, Pagano A, De Michieli F, et al. Comparison of miglitol and glibenclamide in non insulin-dependent diabetic patients. [Italian]. Giornale Italiano di Diabetologia 1993;13(4):383-388. [MEDLINE: 463]
52. Marena S, Pagani A, Montegrosso G, Boella G, Pagano A, De Michieli F, et al. Miglitol vs Glibenclamide in non-insulin dependent diabete mellitus. European Journal of Clinical Investigation 1993;23(Suppl 1):A43. [MEDLINE: 496]
53. Pagano G, Marena S, Corgiat-Mansin L, Cravero F, Giorda C, Bozza M, et al. Comparison of miglitol and glibenclamide in diet-treated type 2 diabetic patients. Diabete & Metabolisme 1995;21(3):162-167. [MEDLINE: 147]
54. Mauersberger H, Rosenthal JH. Wirkung von endogenem Insulin sowie Acarbose oder Glibenclamide in der Therapie der Hypertonie bei Typ-2-Diabetikern. CF-Journal 2001, (1):26-28. [MEDLINE: 502]
55. Rosenthal JH, Mauersberger H. Effects on blood pressure of the alpha-glucosidase inhibitor acarbose compared with the insulin enhancer glibenclamide in patients with hypertension and type 2 diabetes mellitus. Clinical Drug Investigation 2002;22(10):695-701. [MEDLINE: 492]
56. Rosenthal JH, Mauersberger H. Hypertension in type 2-diabetic patients - Effects of endogenous insulin and antidiabetic therapies. American Journal of Hypertension 2000;13(4 Suppl 1):S81. [MEDLINE: 495]
57. Bayer Vital GmbH, Company K.H. Efficacy and tolerability of miglitol (Bay m 1099) and acarbose (Bay g 5421) in type II diabetes, Report no: R6245 (Data on File). 1994. [MEDLINE: 514]
58. Rybka J, Goke B, Sissmann J. European comparative study of 2 alpha-glucosidase inhibitors, miglitol and acarbose. Diabetes 1999;48(Suppl. 1):101. [MEDLINE: 513]
59. Salman S, Salman F, Satman I, Yilmaz Y, Ozer E, Sengul A, et al. Comparison of acarbose and gliclazide as first-line agents in patients with type 2 diabetes. Current Medical Research and Opinion. 2001;16(4):296-306. [MEDLINE: 112]
60. Santeusanio F, Ventura MM, Contadini S, Compagnucci P, Moriconi V, Zaccarini P, et al. Efficacy and safety of two different dosages of acarbose in non-insulin dependent diabetic patients treated by diet alone. Diabetes, Nutrition & Metabolism - Clinical & Experimental 1993;6(3):147-154. [MEDLINE: 468]
61. Scott R, Lintott CJ, Zimmet P, Campbell L, Bowen K, Welborn T. Will acarbose improve the metabolic abnormalities of insulin-resistant type 2 diabetes mellitus?. Diabetes Research and Clinical Practice 1999;43(3):179-185. [MEDLINE: 5]
62. Segal P, Feig PU, Schernthaner G, Ratzmann KP, Rybka J, Petzinna D, et al. The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone. Diabetes Care 1997;20(5):687-691. [MEDLINE: 150]
63. Fölsch UR, Spengler M, Boehme K, Sommerauer B. Efficacy of glucosidase inhibitors compared to sulphonylureas in the treatment and metabolic control of diet treated Type II diabetic subjects: Two long-term comparative studies. Diabetes, Nutrition & Metabolism 1990;3(Suppl. 1):63-68. [MEDLINE: 82]
64. Spengler M, Hansel G, Boehme K. 6 Months monotherapy of NIDDM with acarbose or glibenclamide. New Aspects in Diabetes. Treatment Strategies with Alpha-Glucosidase Inhibitors. Third International Symposium on Acarbose. Berlin - New York: Walter de Gruyter, 1992:243-6. [MEDLINE: 501]
65. Spengler M, Hansel G, Boehme K. Efficacy of 6 months monotherapy with glucosidase inhibitor acarbose versus sulphonylurea glibenclamide on metabolic control of dietary treated type II diabetics (NIDDM). Hormone & Metabolic Research 1992, (Supp 26):50-51. [MEDLINE: 479]
66. Spengler M, Hänsel G, Boehme K. Efficacy of 6 months monotherapy with glucosidase inhibitor acarbose versus sulphonylurea glibenclamid on metabolic control of dietary treated type II diabetics. European Journal of Clinical Investigation. 1989; Vol. 19, issue 2 part II:A71. [MEDLINE: 498]
67. Spengler M, Hänsel, M, Boehme, K. Acarbose and glibenclamide in type II diabetes [Acarbose und Glibenclamid bei Typ-II-Diabetes]. Zeitschrift für Allgemeinmedizin 1990;65(22):606-610. [MEDLINE: 480]
68. Takami K, Takeda N, Nakashima K, Takami R, Hayashi M, Ozeki S, et al. Effects of dietary treatment alone or diet with voglibose or glyburide on abdominal adipose tissue and metabolic abnormalities in patients with newly diagnosed type 2 diabetes. Diabetes Care 2002;25(4):658-662. [MEDLINE: 482]
69. Van de Laar FA, Lucassen PLBJ, Kemp J, Van de Lisdonk EH, Van Weel C, Rutten GEHM. Is acarbose equivalent to tolbutamide as first treatment for newly diagnosed diabetes in general practice? A randomised controlled trial. Diabetes Research and Clinical Practice 2004;63(1):57-65. [MEDLINE: 136]
70. Zheng GF, Wang JP, Zhang H, Hu ZX, Liu J, Xiao JZ, et al. Clinical observation on glucobay treatment for NIDDM. [Chinese]. Chinese Journal of Endocrinology 1995;11(3):163-164. [MEDLINE: 488]
71. Bachmann W, Petzinna D, Sotiros A, Wascher T. Long-Term Improvement of Metabolic Control by Acarbose in Type 2 Diabetes Patients Poorly Controlled with Maximum Sulfonylurea Therapy. Clinical Drug Investigation 2003;23(10):679-686. [MEDLINE: 508]
72. Bayer AG. Study No. 541. Data on file, Bayer. [MEDLINE: 507]
73. Bayer AG. Study No. 656. Data on file, Bayer. [MEDLINE: 509]
74. Coniff RF, Shapiro JA, Seaton TB, Hoogwerf BJ, Hunt JA. A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes. Diabetes Care 1995;18(7):928-932. [MEDLINE: 430]
75. de Leiva A, Piñón F, Tébar J, Escobar-Jiménez F, De la Calle H, Herrera-Pombo JL, et al. Clinical efficacy and tolerance to acarbose in the treatment of non-insulin-dependent diabetic patients [Eficacia clínica y tolerancia de la acarbosa en el tratamiento de pacientes diabéticos no dependientes de la insulina (tipo II)]. Medicina clinica 1993;100(10):368-371. [MEDLINE: 126]
76. Escobar-Jimenez F, Barajas C, de Leiva A, Cano FJ, Masoliver R, Herrera-Pombo JL, et al. Efficacy and tolerability of miglitol in the treatment of patients with non-insulin-dependent diabetes mellitus. Current Therapeutic Research, Clinical & Experimental 1995;56(3):258-268. [MEDLINE: 2]
77. Fujita H, Yamagamu T, Ahshima K. Long-term ingestion of a fermented soybean-derived Touchi-extract with alpha-glucosidase inhibitory activity is safe and effective in humans with borderline and mild type-2 diabetes. Journal of Nutrition 2001;131(8):2105-2108. [MEDLINE: 499]
78. Hasche H, Mertes G, Bruns C, Englert R, Genthner P, Heim D, et al. Effects of acarbose treatment in Type 2 diabetic patients under dietary training: a multicentre, double-blind, placebo-controlled, 2-year study. Diabetes, Nutrition & Metabolism 1999;12(4):277-285. [MEDLINE: 1]
79. Holman RR, Steemson J, Turner RC. Post-prandial glycaemic reduction by an alpha-glucosidase inhibitor in type 2 diabetic patients with therapeutically attained basal normoglycaemia. Diabetes Research (Edinburgh, Lothian) 1991;18(4):149-153. [MEDLINE: 139]
80. Ikeda T, Murao A, Santou Y, Murakami H, Yamamoto R. Comparison of the clinical effect of acarbose and voglibose on blood glucose in non-obese, non-insulin dependent diabetes mellitus [Japanese]. Therapeutic Research 1998;19(9):271-278. [MEDLINE: 226]
81. Jenney A, Proietto J, O'Dea K, Nankervis A, Traianedes K, D'Embden H. Low-dose acarbose improves glycemic control in NIDDM patients without changes in insulin sensitivity. Diabetes Care 1993;16(2):499-502. [MEDLINE: 140]
82. Rosak C, Haupt E, Walter T, Werner J. The effect of combination treatment with acarbose and glibenclamide on postprandial glucose and insulin profiles: additive blood glucose lowering effect and decreased hypoglycaemia. Diabetes, Nutrition & Metabolism 2002;15(3):143-151. [MEDLINE: 491]
83. Rosenbaum P, Peres RB, Zanella MT, Ferreira SRG. Improved glycemic control by acarbose therapy in hypertensive diabetic patients: effects on blood pressure and hormonal parameters. Brazilian Journal of Medical and Biological Research 2002;35(8):877-884. [MEDLINE: 490]
84. Soonthornpun S, Rattarasarn C, Thamprasit A, Leetanaporn K. Effect of acarbose in treatment of type II diabetes mellitus: a double-blind, crossover, placebo-controlled trial. Journal of the Medical Association of Thailand 1998;81(3):195-200. [MEDLINE: 12]
85. Wang H, Xu WH, Wang GY. An evalualion on efficacy of acarbose interfering treatment on IGT. Shanxi Clinical Medicine Journal 2000;9(2):116-117. [MEDLINE: 503]
86. Holman R. Early Diabetes Intervention Study (EDIT). The National Research Register 2003, issue 1. [N0162013485]
87. Sa-adu A. A one-year multicentre, international, randomised, double-blind comparison of Mitiglinide (10to40mgTID) and Acarbose (50mgODto100mgTID) administered orally for the treatment of elderly type 2 diabetic patients. The National Research Register 2003, issue 1. [N0235102775]
88. Ryder REJ. BIOS - A long-term study to investigate the effects of acarbose (Glucobay) in preventing or delaying deterioration in glycaemic status in non-insulin dependent diabetes well controlled on diet alone. The National Research Register 2003, issue 1. [N0064018154]
89. Whitby RJ. A long-term study to investigate the effects of acarbose (glucobay) in preventing or delaying deterioration in glycaemic status in non-insulin diabetes well controlled on diet alone. The National Research Register 2003, issue 1:Publication ID: B0201167. [Publication ID: B0201167]
90. American Diabetic Association. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-97.
91. American Diabetic Association. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1999;22(Suppl 1):S1-114.
92. Begg CB, Mazumbar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-1101.
93. Breuer HW. Review of acarbose therapeutic strategies in the long-term treatment and in the prevention of type 2 diabetes. International Journal of Clinical Pharmacology and Therapeutics 2003;41(10):421-440. [MEDLINE: 113]
94. Campbell LK, White JR, Campbell RK. Acarbose: its role in the treatment of diabetes mellitus [see comments]. The Annals of Pharmacotherapy 1996;30(11):1255-62. [MEDLINE: 104]
95. Campbell LK, Baker DE, Campbell RK. Miglitol: assessment of its role in the treatment of patients with diabetes mellitus. The Annals of Pharmacotherapy 2000;34(11):1291-1301. [MEDLINE: 7]
96. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359(9323):2072-2077. [MEDLINE: 169]
97. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA : the journal of the American Medical Association 2003;290(4):486-494. [MEDLINE: 168]
98. Cohen J. A coefficient of agreement for nominal scales. Educational and Psychological Measurement 1960;20:37-46.
99. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. The New England Journal of Medicine 2000;342(25):1887-1892. [MEDLINE: 24]
100. Anonymous. A desktop guide to Type 2 diabetes mellitus. European Diabetes Policy Group 1999. Diabetic Medicine 1999;16(9):716-730. [MEDLINE: 135]
101. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. British Medical Journal 1997;315(7109):629-34. [MEDLINE: 16]
102. Fölsch UR, Spengler M, Boehme K, Sommerauer B. Efficacy of glucosidase inhibitors compared to sulphonylureas in the treatment and metabolic control of diet treated Type II diabetic subjects: Two long-term comparative studies. Diabetes, Nutrition & Metabolism 1990;3(Suppl. 1):63-68. [MEDLINE: 82]
103. Hanefeld M, Petzinna D, Cagatay M. MeRIA Study: Acarbose Reduces the Incidence of Infarction in Patients with Type 2 Diabetes - Metaanalysis of Placebo-Controlled Long-Term Studies. Poster presentation, IDF Paris August 25th. IDF Paris August 25th 2003, 2003. [MEDLINE: 163]
104. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analyses of seven long-term studies. European Heart Journal 2004;25:10-16. [MEDLINE: 163]
105. Hedges LV. Modeling publication selection effects in meta-analysis. Statistical Science 1992;7:246-255.
106. Kaiser T, Sawicki PT. Acarbose for prevention of diabetes, hypertension and cardiovascular events? A critical analysis of the STOP-NIDDM data. Diabetologia 2004. [MEDLINE: 114]
107. Laube H. Acarbose. An Update of Its Therapeutic Use in Diabetes Treatment. Clinical Drug Investigation 2002;22(3):141-156. [MEDLINE: 111]
108. Lebovitz HE. Alpha-Glucosidase inhibitors as agents in the treatment of diabetes. Diabetes Reviews 1998;6(2):132-145. [MEDLINE: 112]
109. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. British Medical Journal 2003;326(7400):1167-1170. [MEDLINE: 23]
110. Martin AE, Montgomery PA. Acarbose: an alpha-glucosidase inhibitor. American Journal of Health-system Pharmacy 1996;53(19):2277-2290. [MEDLINE: 34]
111. Navarro J, Valdivieso M, Bonet A, Navarro A, Gosalbes V. Oral combination therapy for type 2 diabetes mellitus (Protocol for a Cochrane Review). The Cochrane Library Issue 4. [MEDLINE: 167]
112. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979;28:1039-57.
113. Reaven GM, Lardinois CK, Greenfield MS, Schwartz HC, Vreman HJ. Effect of acarbose on carbohydrate and lipid metabolism in NIDDM patients poorly controlled by sulfonylureas. Diabetes Care 1990;13 Suppl 3:32-36. [MEDLINE: 105]
114. Rutten GEHM, Verhoeven S, Heine RJ, De Grauw WJC, Cromme PVM, Reenders K, et al. Dutch College of General Practitioners.Guidelines on Type 2 Diabetes [NHG Standaard diabetes mellitus type 2]. Huisarts en Wetenschap 2000;42(2):67-84. [MEDLINE: 119]
115. Scott LJ, Spencer CM. Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus. Drugs 2000;59(3):521-549. [MEDLINE: 11]
116. Van de Laar FA, Lucassen PLBJ. No evidence for a reduction of myocardial infarctions by acarbose. European Heart Journal 2004;25(13):1179.
117. WHO Expert Committee on Diabetes Mellitus. Second report. Technical Report Series 646. World Health Organisation, 1980.
118. World Health Organisation. Diabetes Mellitus: Report of a WHO Study Group. Technical Report Series No. 727. World Health Organisation, 1985.
119. Alberti KM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic Medicine 1998;15:539-53.
120. Van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, Rutten GE, Van Weel C. Alpha-glucosidase inhibitors for patients with type 2 diabetes. Results from a Cochrane systematic review and meta-analysis. Diabetes Care 2005;28(1):154-163.